Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up
Brief Summary: Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women. This study will evaluate the immunogenicity and safety of the HPV-16/18 L1 VLP AS04 vaccine.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK580299 (CervarixTM) | Arm Label: Engerix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-BTM | Intervention Type: BIOLOGICAL; Name: GSK580299 (CervarixTM); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-BTM; Assigned to Arm(s): Engerix Group
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 L1 VLP AS04 (Cervarix TM) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1 VLP AS04 (Cervarix TM); Assigned to Arm(s): Cervarix Group
C: Arm Label: A: HAART naive or no HAART in past 6 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV vaccine for strains -6, -11, -16, and -18 | Arm Label: B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV vaccine for strains -6, -11, -16, and -18 | Intervention Type: BIOLOGICAL; Name: HPV vaccine for strains -6, -11, -16, and -18; Assigned to Arm(s): A: HAART naive or no HAART in past 6 months, B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months
D: Arm Label: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20 | Arm Label: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40 | Arm Label: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80 | Arm Label: Placebo (mcg) (Aluminum Adjuvant) 225; Type: EXPERIMENTAL; Interventions: Biological: Placebo (mcg) (Aluminum Adjuvant)225 | Arm Label: Placebo (mcg) (Aluminum Adjuvant) 450; Type: EXPERIMENTAL; Interventions: Biological: Placebo (mcg) (Aluminum Adjuvant) 450 | Intervention Type: BIOLOGICAL; Name: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20; Assigned to Arm(s): Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine | Intervention Type: BIOLOGICAL; Name: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40; Assigned to Arm(s): Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40 | Intervention Type: BIOLOGICAL; Name: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80; Assigned to Arm(s): Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80 | Intervention Type: BIOLOGICAL; Name: Placebo (mcg) (Aluminum Adjuvant)225; Assigned to Arm(s): Placebo (mcg) (Aluminum Adjuvant) 225 | Intervention Type: BIOLOGICAL; Name: Placebo (mcg) (Aluminum Adjuvant) 450; Assigned to Arm(s): Placebo (mcg) (Aluminum Adjuvant) 450

Answer: B